{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:07:19Z","timestamp":1791612439505,"version":"4.3.4"},"reference-count":47,"publisher":"Bioscientifica","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":224,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study evaluated adverse events reported with tirzepatide, a dual GIP\/GLP-1 receptor agonist approved for type 2 diabetes and obesity, using real-world data from the FDA Adverse Event Reporting System. A disproportionality analysis was conducted on reports from May 2022 to the fourth quarter of 2024. Reports were deduplicated, normalized using standardized medical terminology, and analyzed using four disproportionality analysis algorithms. Significant signals required meeting all four methods\u2019 criteria with at least three cases. Among 20,350 adverse event reports (68.0% female; median age 50.4 years), 105 significant adverse events were identified. Common events included gastrointestinal disorders (nausea and diarrhea) and injection-site reactions. The strongest signals were injection-site coldness and belching. Known risks such as pancreatitis (190 cases) and hypoglycemia (115 cases) were confirmed. Novel signals included upper respiratory infections and postmenopausal hemorrhage. The median onset time was 26 days, with 50% of events occurring within the first month. Older adults (65 years or older) experienced earlier onset (12 versus 31 days, significant difference). This analysis is consistent with known gastrointestinal and pancreatic risks of tirzepatide from prior clinical studies and identifies potential new safety concerns, underscoring the need for vigilant monitoring, particularly during initial treatment phases.<\/jats:p>","DOI":"10.1530\/ec-25-0205","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:14:14Z","timestamp":1752138854000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":6,"title":["Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database"],"prefix":"10.1530","volume":"14","author":[{"given":"Zhenpo","family":"Zhang","sequence":"first","affiliation":[{"name":"College of Pharmacy, Jinan University 1 , , ,","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxiong","family":"Li","sequence":"additional","affiliation":[{"name":"Zhuhai Jiuhuatong Biomedical Technology Co., Ltd 2 , , ,","place":["Zhuhai, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Zheng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University 1 , , ,","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yankun","family":"Liang","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University 1 , , ,","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Food Science and Engineering, South China University of Technology 3 , , ,","place":["Guangzhou, Guangdong, China"]},{"name":"Medical Department, Guangdong Hospital of Traditional Chinese Medicine 4 , , ,","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0594-9181","authenticated-orcid":true,"given":"Ling","family":"Su","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jinan University 1 , , ,","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"2026070711000233700_bib1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2337\/dc20-2372","article-title":"Type 2 diabetes subgroups, risk for complications, and differential effects due to an intensive lifestyle intervention","volume":"44","author":"Bancks","year":"2021","journal-title":"Diabetes Care"},{"key":"2026070711000233700_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/00325481.2019.1549459","article-title":"Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease","volume":"131","author":"Kelly","year":"2019","journal-title":"Postgrad Med"},{"key":"2026070711000233700_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2017.4","article-title":"A systematic review on the impact of diabetes mellitus on the ocular surface","volume":"7","author":"Shih","year":"2017","journal-title":"Nutr Diabetes"},{"key":"2026070711000233700_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2019.05.003","article-title":"Effectiveness of a theory-based foot care education program (3STEPFUN) in improving foot self-care behaviours and foot risk factors for ulceration in people with type 2 diabetes","volume":"152","author":"Nguyen","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"2026070711000233700_bib5","volume-title":"IDF Diabetes Atlas","author":"Magliano","edition":"10th edn"},{"key":"2026070711000233700_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107031","article-title":"Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis","volume":"199","author":"Ding","year":"2024","journal-title":"Pharmacol Res"},{"key":"2026070711000233700_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(16)30175-1","article-title":"Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents","volume":"388","author":"Global BMI Mortality Collaboration","year":"2016","journal-title":"Lancet"},{"key":"2026070711000233700_bib8","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American heart association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2026070711000233700_bib9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/molecules25081987","article-title":"Type 2 diabetes mellitus: a review of multi-target drugs","volume":"25","author":"Artasensi","year":"2020","journal-title":"Molecules"},{"key":"2026070711000233700_bib10","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40265-022-01746-8","article-title":"Tirzepatide: first approval","volume":"82","author":"Syed","year":"2022","journal-title":"Drugs"},{"key":"2026070711000233700_bib11","first-page":"656","article-title":"FDA approves tirzepatide as first drug for obstructive sleep apnea","volume":"333","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"2026070711000233700_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026070711000233700_bib13","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2023-6-1","article-title":"Tirzepatide for type 2 diabetes","volume":"12","author":"Anderson","year":"2023","journal-title":"Drugs Context"},{"key":"2026070711000233700_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.998816","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a bayesian network meta-analysis","volume":"13","author":"Guan","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026070711000233700_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2024.108800","article-title":"Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: a step closer to drug-induced diabetes remission?","volume":"38","author":"Popovic","year":"2024","journal-title":"J Diabetes Complicat"},{"key":"2026070711000233700_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1004044","article-title":"Clinical perspectives on the use of the GIP\/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity","volume":"13","author":"Gallwitz","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070711000233700_bib17","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/ph14100991","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized phase II\/III trials","volume":"14","author":"Bhagavathula","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026070711000233700_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026070711000233700_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1502047","article-title":"A real-world data analysis of tirzepatide in the FDA Adverse Event Reporting System (FAERS) database","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026070711000233700_bib20","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14740338.2024.2376686","article-title":"Data mining study on adverse events of tirzepatide based on FAERS database","volume":"24","author":"Huo","year":"2025","journal-title":"Expet Opin Drug Saf"},{"key":"2026070711000233700_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1463657","article-title":"Analysis of tirzepatide in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups","volume":"15","author":"Ou","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026070711000233700_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/14740338.2025.2468860","article-title":"Post-marketing safety monitoring of tirzepatide: a pharmacovigilance study based on the FAERS database","author":"Chen","year":"2025","journal-title":"Expet Opin Drug Saf"},{"key":"2026070711000233700_bib23","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinological Invest"},{"key":"2026070711000233700_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2106\/JBJS.K.01181","article-title":"Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the research on adverse drug events and reports (RADAR) project","volume":"95","author":"Edwards","year":"2013","journal-title":"J Bone Jt Surg Am Vol"},{"key":"2026070711000233700_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expet Opin Drug Saf"},{"key":"2026070711000233700_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"2026070711000233700_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026070711000233700_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026070711000233700_bib29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"2026070711000233700_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Statistician"},{"key":"2026070711000233700_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the surmount clinical development program","volume":"31","author":"le Roux","year":"2023","journal-title":"Obesity"},{"key":"2026070711000233700_bib32","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/dom.14952","article-title":"Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)","volume":"25","author":"Kiyosue","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026070711000233700_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070711000233700_bib34","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026070711000233700_bib35","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"2026070711000233700_bib36","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.2337\/dci21-0004","article-title":"Response to comment on Rosenstock et al. impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. diabetes care 2020;43:2509\u20132518","volume":"44","author":"Rosenstock","year":"2021","journal-title":"Diabetes Care"},{"key":"2026070711000233700_bib37","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"2026070711000233700_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1121387","article-title":"A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist \u2013 is its safety profile acceptable?","volume":"14","author":"Meng","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070711000233700_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"2026070711000233700_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"2026070711000233700_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1016639","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026070711000233700_bib42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"2026070711000233700_bib43","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1080\/00365521.2018.1530297","article-title":"Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs","volume":"53","author":"Rehfeld","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"2026070711000233700_bib44","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz175","article-title":"GIP and GLP-1 receptor antagonism during a meal in healthy individuals","volume":"105","author":"Gasbjerg","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711000233700_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070711000233700_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1041044","article-title":"Optimal dose of tirzepatide for type 2 diabetes mellitus: a meta-analysis and trial sequential analysis","volume":"9","author":"Yu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026070711000233700_bib47","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/14\/7\/EC-25-0205.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/14\/7\/EC-25-0205.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0205\/9681\/ec-25-0205.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0205\/9681\/ec-25-0205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:30:08Z","timestamp":1783438208000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/14\/7\/e250205\/1420\/Tirzepatide-safety-in-type-2-diabetes-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0205","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"e250205"}}